Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteins
The disclosure relates to nucleic acids mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids are suitable for use in inducing an immune response to HIV-1 in a human.
1. An immunogenic composition comprising a recombinant polypeptide comprising the amino acid sequences of SEQ ID NO:221 (B.acute.con1059).
2. The immunogenic composition of claim 1 , further comprising an adjuvant.
3. An immunogenic composition comprising the recombinant polypeptide of SEQ ID NO:221 (B.acute.con1059).
4. The immunogenic composition of claim 3 , further comprising an adjuvant.
5. A method of inducing an immune response against HIV-1 in a host comprising administering to the host the composition of claim 2 in an amount sufficient to effect the induction.
6. A method of inducing an immune response against HIV-1 in a host comprising administering to the host the composition of claim 4 in an amount sufficient to effect the induction.
7. An immunogenic composition comprising a nucleic acid comprising nucleotides encoding the recombinant polypeptide of SEQ ID NO:221 (B.acute.con1059).
8. The immunogenic composition of claim 7 , comprising a nucleic acid encoding the recombinant of SEQ ID NO:221 (B.acute.con1059).
9. The immunogenic composition of claim 7 , further comprising an adjuvant.
10. The immunogenic composition of claim 8 , further comprising an adjuvant.
11. The immunogenic composition of claim 5 , wherein the nucleic acid is operably linked to a promoter in a vector.
12. The immunogenic composition of claim 10 , wherein the nucleic acid is operably linked to a promoter in a vector.
13. The immunogenic composition of claim 11 , wherein the vector is viral vector.
14. The immunogenic composition of claim 12 , wherein the vector is viral vector.
15. A method of inducing an immune response against HIV-1 in a host comprising administering to the host the composition of claim 9 in an amount sufficient to effect the induction.
16. A method of inducing an immune response against HIV-1 in a host comprising administering to the host the composition of claim 10 in an amount sufficient to effect the induction.
17. A method of inducing an immune response against HIV-1 in a host comprising administering to the host the composition of claim 11 in an amount sufficient to effect the induction.
18. A method of inducing an immune response against HIV-1 in a host comprising administering to the host the composition of claim 12 in an amount sufficient to effect the induction.